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INTRODUCTION
Prematurity is the leading cause of perinatal
morbidity and mortality.
1
 Despite the availability of
tocolytic drugs, aggressive surveillance techniques,
and other treatment and prevention strategies, no
change has been observed in premature delivery
rate since the 1950s.
2
 It is well known that twins
have significantly higher perinatal mortality than
singletons, with a rate 4 to 10 times greater in twins
than in singletons being reported.
3-4
 The high
perinatal mortality is associated with the increased
rate of preterm delivery. Various approaches have
been proposed in order to reduce the prematurity
rate in twin pregnancies, such as prophylactic
cervical cerclage, monitoring of uterine activity, long
term tocolysis and bed rest. However, most published
studies
5-9
 have not been able to demonstrate effective
methods that significantly decrease the rate of
preterm deliveries in twin pregnancies. Over the last
seven years, the presence of fetal fibronectin in the
cervix or vagina has been investigated as a possible
marker for the risk of preterm birth. Fetal fibronectin
in cervical fluid can provide direct evidence of
pathologic changes at the interface of fetal and
maternal tissues. Thus, fetal fibronectin as a screening
test could assist the clinician in the identification of
twin pregnancies at high risk for preterm birth.
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Context: The presence of fetal fibronectin in the cervix or
vagina has been investigated as a possible marker for the risk
of preterm birth. Fetal fibronectin in cervical fluid can provide
direct evidence of pathologic changes at the interface of fetal
and maternal tissues.
Objective: To evaluate the presence of fetal fibronectin as
a predictor of premature delivery in twin pregnancies in
relation to gestational age.
Design: Acuracy study.
Setting: University referral unit.
Participants: 52 pregnant women with twin pregnancies
and gestational age of between 24 and 34 weeks.
Main measurements: Sensivity, specifity, predictive
values and relative risk ratios of the correlation between
fetal fibronectin and preterm birth before 34 and 37 weeks
using an immediate-reading membrane test on
cervicovaginal secretions obtained from participants.
Result: The sensitivity varied between 66.7% and 85.7%,
whereas the specificity was from 58.3% to 81.8%
according to gestational age at the time of sampling. The
relative risk of spontaneous preterm birth after a positive
fetal fibronectin test, as compared with a negative fetal
fibronectin test, rose from 2.8 at 24-26 weeks to 4.1 at 27-
30 weeks. Analyses of the risk of delivery before 34 weeks
were not statistically significant.
Conclusion: Fetal fibronectin in the cervicovaginal
secretions of patients with twin pregnancies is a useful tool
for the early identification of twin pregnancies likely to
deliver before 37 weeks. However, the clinical value of the
fibronectin test is limited because of low indices for
prediction of delivery before 34 weeks. The best period for
performing the fetal fibronectin test in twin pregnancies to
predict preterm delivery is between 27 and 30 weeks.
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The purpose of this study was to evaluate the
efficacy of fetal fibronectin test in predicting preterm
delivery in twin pregnancies in relation to gestational
age at the time of sampling.
METHODS
The study was done at Hospital Maternidade
“Leonor Mendes de Barros” and Hospital São Paulo
(Universidade Federal de São Paulo) between June
1994 and August 1996. After informed consent
was obtained from all patients, gestational age was
established using the date of the last menstrual period
and was confirmed by early ultrasonography.
Fifty-nine women were prospectively enrolled
in the study and none were lost during it. Five of
them were excluded because of medical
complications that necessitated preterm delivery:
severe pre-eclampsia (3 cases), eclampsia (1 case)
and fetal distress (1 case). Two patients who delivered
at term after using tocolytic agents to inhibit preterm
labor were also excluded. Conversely, nine patients
who underwent tocolysis unsuccessfully were
included in the study. Thus, 52 patients remained
for analysis.
Samples of cervicovaginal secretions were
collected every two weeks between 24 and 34
weeks of gestation. The presence of fetal fibronectin
was determined qualitatively using a bedside
membrane immunoassay. No attempt was made to
control patient treatment and management during
prenatal care based on fetal fibronectin test results.
The fetal fibronectin results were not communicated
to the obstetric team and therefore did not influence
subsequent patient management. Preterm birth was
defined as delivery before 37 weeks of gestation.
Because the test results are qualitative and
based on the observation of colored spot,  the
researcher and two independent observers
compared the color reaction of each test with a
standard chart supplied with each kit, showing an
example of the reaction intensity to define the test as
positive or negative. After recording the results found
by each observer, the samples were excluded from
the study in cases of discordant opinions.
Cervicovaginal samples with visible blood at swab
were also excluded.
Statistical Methods. Correlation between the
time of delivery and fetal fibronectin test result was
performed by means of sensitivity, specificity and
predictive values. The data was analyzed using
relative risk ratios.
RESULTS
Twenty-eight (53.8%) delivered before 37
weeks. A total of 270 samples were collected from
these patients during the study. The average number
of samples obtained per patient  was 5.2. Twenty
three samples were excluded, because of discordant
results between the observers (13 cases) or presence
of blood at swab (10 cases). Therefore, we analyzed
247 samples for the prediction of preterm delivery.
Table 1 presents the sensitivity, specificity,
positive and negative predictive value for
spontaneous preterm delivery in relation to
gestational age at the time of sampling. The periods
of gestational age considered were 24 to 26, 27 to
30 and 31 to 34 weeks of gestation. Twenty-one
women out of a total of 43 delivered preterm when
the test was performed at 24 to 26 weeks of
gestation. Twenty-eight out of a total of 52 delivered
preterm when the test was performed at 27 to 30
weeks of gestation. Twenty-six preterm births occurred
out of a total of 50 women who underwent the test
at 31 to 34 weeks. The sensitivity varied between
66.7% and 85.7%, the specificity rose from 58.3%
to 81.8%, whereas positive and negative predictive
values were equivalent in those three periods. Table
1 also shows that the relative risk (RR) for preterm
birth was greater at 27 to 30 weeks than at 24 to
26 weeks and 31 to 34 weeks.
Because preterm birth before than 34 weeks
is associated with the worst perinatal outcomes, we
determined the value of the fetal fibronectin test in
the prediction of  spontaneous delivery before 34
weeks in those three different time periods. Nine
patients out of a total of 43 delivered before 34
weeks when the test was performed at 24 to 26
weeks of gestation. Ten women out of a total of 52
delivered before 34 weeks when the test was
performed at 27 to 30 weeks of gestation. Six
preterm births occurred out of a total of 50 women
who underwent the test at 31 to 34 weeks. In Table
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2, it can be seen that the sensitivity and negative
predictive values of the fetal fibronectin test at 27 to
30 weeks were better at predicting delivery before
34 weeks when compared with the other two
intervals. However, the relative  risk was not
statistically significant.
DISCUSSION
The major cause of increased perinatal
mortality in twin pregnancies is preterm delivery.
10
The availability of a rapid search for the presence of
cervical fetal fibronectin could improve our ability to
efficiently identify patients at risk for preterm delivery.
The rapid result membrane test was comparable to
the standard fetal fibronectin in cervical vaginal




 studied how various patterns
of fetal fibronectin testing were related to spontaneous
preterm birth in singleton pregnancies, and reported
that the last test result seems to be the best predictor of
subsequent spontaneous preterm delivery. In twin
pregnancies, however, it seems that the 27 to 30-
week sampling period is the most appropriate moment
to evaluate the risk of preterm delivery in twin
gestations because the number of false positives in
this interval is less than in the other two.
Nageotte et al
13
 evaluated the predictive
efficacy of weekly cervicovaginal fetal fibronectin
determinations between 20 and 37 weeks in 102
asymptomatic singleton pregnancies. They reported
that fetal fibronectin had high sensitivity (90.6%) but
low specificity (44.3%) for prediction of preterm
delivery. According to these authors, their large
number of false-positive results may reflect degrees of








high sensitivity (90.9%) and low specificity (68.5%)
in 68 patients with multiple gestations who underwent
weekly sampling of cervical and vaginal secretions.
We believe that the fetal fibronectin test has
great potential for improving the clinician’s ability to
select patients for preventive approaches and
tocolytic drug therapy and for reducing the number
Table 2 - Predictive values for spontaneous preterm delivery before 34 weeks in
accordance with the gestational age at the time of the fetal fibronectin test
Gestational Sensitivity Specificity Positive predictive Negative predictive Relative Risk
age (95% CI) (95% CI) value (95% CI) value (95% CI) (95% CI)
24 to 26 55.6% 61.8% 27.8% 84.0% 1.7
(22.7 to 84.7) (43.6 to 77.3) (10.7 to 53.6) (63.1 to 94.7) ( 0.5 to 5.6)
27 to 30 80.0% 45.2% 25.8% 90.5% 2.7
(44.2 to 96.5) (30.2 to 61.2) (12.5 to 44.9) (68.2 to 98.3) ( 0.6 to 11.5)
31 to 34 66.7% 36.6% 18.8% 83.3% 1.1
(30.9 to 91.0) (22.6 to 53.1) (7.9 to 37.0) (57.7 to 95.6) ( 0.3 to 4.0)
CI = Confidence interval
Table 1 - Predictive values for spontaneous preterm delivery before 37 weeks
in accordance with the gestational age at the time of the fetal fibronectin test
Gestational Sensitivity Specificity Positive predictive Negative predictive Relative Risk
age (95% CI) (95% CI) value (95% CI) value (95% CI) (95% CI)
24 to 26 66.7% 81.8% 77.8% 72.0% 2.8
(43.1 to 84.5) (59.0 to 94.0) (51.9 to 92.6) (50.4 to 87.1) (1.4 to 5.5)
27 to 30 85.7% 70.8% 77.4% 80.9% 4.1
(66.4 to 95.3) (48.8 to 86.6) (58.5 to 89.7) (57.4 to 93.7) (1.7 to 10)
31 to 34 84.6% 58.3% 68.8% 77.8% 3.1
(64.3 to 95.0) (36.9 to 77.2) (49.9 to 83.3) (51.9 to 92.6) (1.3 to 7.6)
CI = Confidence interval
Sao Paulo Med J/Rev Paul Med 1999; 117(3):121-4.
124
of women who unnecessarily receive treatment for
a perceived threat of preterm labor. However, despite
the high sensitivity and negative predictive value
towards delivery before 34 weeks, the period when
the majority of perinatal  mortality is likely to occur,
the analysis of the data showed that the relative risk
of a positive fetal fibronectin test is not statistically
significant when compared with the negative test.
Therefore, we found no evidence to support the idea
that the fetal fibronectin test could reduce the perinatal
mortality in twin pregnancies.
In conclusion, the fetal fibronectin test seems
to be a useful tool in clinical practice for early
identification of twin pregnancies likely to develop
preterm labor. However, the clinical value of the
fibronectin test is limited because of low indices for
prediction of delivery before 34 weeks. The best
period for performing the fetal fibronectin test in twin
pregnancies for prediction of preterm delivery  is
between 27 and 30 weeks.
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RESUMO
Objetivo: Avaliar a presença da fibronectina fetal como fator de predição do parto prematuro na prenhez gemelar de acordo com
a idade gestacional. Tipo de Estudo: Estudo de acurácia. Local: Centro de Referência Universitário. Participantes: 52
gestantes com prenhezes gemelares foram submetidas ao teste de imunoensaio de membrana entre 24 e 34 semanas para verificar
a correlação entre a presença de fibronectina fetal na secreção cérvico-vaginal e o risco de parto prematuro antes de 34 e 37
semanas de gestação. Variáveis estudadas: Sensibilidade, especificidade, valores preditivos e risco relativo da correlação entre
a presença de fibronectina fetal na secreção cévico-vaginal e o risco de parto prematuro antes de 34 e 37 semanas de gestação.
Resultado: A sensibilidade variou entre 66,7% e 85,7%, enquanto a especificidade foi de 58,3% a 81,8% de acordo com a
idade gestacional em que o exame foi realizado. O risco relativo para o parto prematuro espontâneo após um teste positivo
comparado ao teste negativo variou de  2,8 entre 24-26 semanas a 4,1 entre 27-30 semanas. Os dados analisados para predição
do parto antes de 34 semanas não mostraram resultados estatisticamente significantes. Conclusão: O teste da fibronectina fetal é
útil para identificação precoce das gemeligestas com risco elevado para o parto prematuro antes de 37 semanas. Contudo, o valor
clínico do teste é limitado devido aos baixos valores de predição para ocorrência do parto antes de 34 semanas.  O melhor
período para a realização do teste para predição do parto prematuro é entre 27 e 30 semanas de gestação.
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